ArticleHuman genomics2026
Genotype-phenotype correlations in phenylketonuria: PAH variants and BH4 responsiveness for treatment design.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundPhenylketonuria (PKU) is an autosomal recessive disorder caused by PAH alterations, leading to elevated phenylalanine (Phe) and neurotoxicity. Newborn screening (NBS) and early therapy improve outcomes. This study aimed to characterize the molecular and phenotypic spectrum of PKU, explore genotype–phenotype correlations, and evaluate the relationship between PAH variants and BH4 responsiveness to guide personalized treatment.
methodsMedical and genetic records of 171 patients diagnosed with hyperphenylalaninemia via NBS were reviewed. Demographic data, diagnostic Phe and tyrosine (Tyr) levels, BH4 loading test results, and genetic analyses including Sanger sequencing, MLPA, and array CGH were assessed. Allelic and genotype–phenotype values were used to estimate variant severity.
results168 carried ≥ 1 PAH variant; three had BH4 metabolism disorders. A total of 63 distinct PAH variants were identified; MLPA detected large deletions in three patients. Five variants (c.1066-11G > A, c.782G > A, c.143T > C, c.898G > T, c.1208 C > T) accounted for > 50% of the cohort. Among 100 patients tested, 41% responded to BH4, with c.782G > A most common (21%). Overall, 68.5% received dietary and/or BH4 therapy.
conclusionThis study contributes to our understanding of PKU’s molecular and phenotypic landscape, highlighting the importance of utilising both genotype and response to the BH4 loading test in the design of personalised treatments, beyond the initial Phe level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.